Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...